The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.
%0 Journal Article
%1 Pouplin2011
%A Pouplin, Thomas
%A Pouplin, Julie Nguyen
%A Van Toi, Pham
%A Lindegardh, Niklas
%A Rogier van Doorn, H.
%A Hien, Tran Tinh
%A Farrar, Jeremy
%A Török, M Estée
%A Chau, Tran Thi Hong
%D 2011
%J Antimicrob Agents Chemother
%K hsv encephalitis
%N 7
%P 3624--3626
%R 10.1128/AAC.01023-10
%T Valacyclovir for herpes simplex encephalitis.
%U http://dx.doi.org/10.1128/AAC.01023-10
%V 55
%X The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.
@article{Pouplin2011,
abstract = {The recommended treatment for herpes simplex encephalitis (HSE) remains intravenous acyclovir. In resource-poor countries, however, intravenous formulations are usually unavailable or unaffordable. We report the penetration of acyclovir into the cerebrospinal fluid (CSF) in patients with HSE, treated with the oral prodrug valacyclovir at 1,000 mg three times daily. The oral therapy achieved adequate acyclovir concentrations in the CSF and may be an acceptable early treatment for suspected HSE in resource-limited settings.},
added-at = {2012-05-16T01:19:34.000+0200},
author = {Pouplin, Thomas and Pouplin, Julie Nguyen and {Van Toi}, Pham and Lindegardh, Niklas and {Rogier van Doorn}, H. and Hien, Tran Tinh and Farrar, Jeremy and Török, M Estée and Chau, Tran Thi Hong},
biburl = {https://www.bibsonomy.org/bibtex/29579164a56da3a24ef2a3a02b5ea1812/aorchid},
doi = {10.1128/AAC.01023-10},
file = {:ID_General/Virus_Non-HIV/AntimicrobAgentsChemother.55.3624.pdf:PDF},
groups = {public},
institution = {Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. tpouplin@oucru.org},
interhash = {332400655b1bc03df571450391c31c57},
intrahash = {9579164a56da3a24ef2a3a02b5ea1812},
journal = {Antimicrob Agents Chemother},
keywords = {hsv encephalitis},
language = {eng},
medline-pst = {ppublish},
month = Jul,
number = 7,
pages = {3624--3626},
pii = {AAC.01023-10},
pmid = {21576427},
timestamp = {2012-05-16T01:19:34.000+0200},
title = {Valacyclovir for herpes simplex encephalitis.},
url = {http://dx.doi.org/10.1128/AAC.01023-10},
username = {aorchid},
volume = 55,
year = 2011
}